Contract Pharma Manufacturing News

  1. Ardena's Nanomedicines Facility Marks €20M Expansion With First GMP Approval 4/18/2024

    Oss, The Netherlands: Ardena, a leading Contract Development and Manufacturing Organization (CDMO) specializing in bringing molecules to clinic, has received Good Manufacturing Practice (GMP) approval from the Dutch Healthcare Authority for its new analytical laboratories in its expanded nanomedicines facility.

  2. ExoXpert Announces Agreement with Neucore Bio to Evaluate Advanced Exosome Loading 4/17/2024

    ExoXpert, a Contract Development and Manufacturing Organization (CDMO) specializing in exosome production and a subsidiary of Exo Biologics, today announces a strategic partnership with Neucore Bio, a next-generation, non-viral engineered delivery technology company to leverage ExoXpert’s platform for evaluation of advanced exosome loading.

  3. Imugene And Kincell Bio Announce Strategic Manufacturing And Process Development Partnership 4/16/2024

    Imugene, Ltd. (“Imugene”)(ASX: IMU) and Kincell Bio, LLC (“Kincell”), announce a strategic manufacturing and process development partnership, which includes the sale of Imugene’s North Carolina Current Good Manufacturing Practice (CGMP) manufacturing facility and the transfer of process and analytical development activities to Kincell.

  4. AmplifyBio And RNAV8 Bio Announce Strategic Partnership To Support mRNA Therapeutic Developers From Sequence Design To GMP Manufacture 4/16/2024

    AmplifyBio, a Contract Development and Manufacturing Organization (CDMO) and Contract Research Organization (CRO) focused on differentiating services that cover target optimization, preclinical safety studies, and manufacturing scale-up, and RNAV8 Bio, an emerging startup focused on mRNA engineering platforms, are partnering to provide a one-stop shop for the development of mRNA therapeutics.

  5. BioHarvest Sciences Announces New Campus For Botanical Synthesis CDMO And Expansion Of Manufacturing Capacity 4/16/2024

    BioHarvest Sciences Inc. (“BioHarvest” or the “Company”) a biotechnology company pioneering its patented Botanical Synthesis technology process, today announced the signing of two agreements: a long term lease agreement for a new 80,000 square ft. facility in Yavne, Israel, and an equipment purchase agreement for 12 state of the art GMP clean rooms.

  6. Medincell Enters Into Strategic Co-Development And Licensing Agreement With Abbvie To Develop Next-Generation Long-Acting Injectable Therapies 4/16/2024

    Medincell today announced a collaboration with AbbVie to co-develop and commercialize up to six therapeutic products across multiple therapeutic areas and indications.

  7. Evergreen Theragnostics Completes $26M Capital Raise To Advance Novel Radiopharmaceutical Pipeline Into The Clinic, Prepare For First Commercial Product Launch, And Expand Industry-Leading CDMO Services 4/16/2024

    Evergreen Theragnostics, Inc., a clinical-stage radiopharmaceutical company, today announced the successful completion of a $26M capital raise supported both by existing shareholders and new institutional investors, Petrichor and LIFTT.

  8. Arvinas Enters Into A Transaction With Novartis, Including A Global License Agreement For The Development And Commercialization Of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 For The Treatment Of Prostate Cancer 4/11/2024

    Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced it has entered into an exclusive strategic license agreement with Novartis (NYSE: NVS) for the worldwide development and commercialization of ARV-766, Arvinas’ second generation PROTAC® androgen receptor (AR) degrader for patients with prostate cancer.

  9. FUJIFILM Diosynth Invests $1.2B In Holly Springs, North Carolina, Manufacturing Facility, Creating 680 New Jobs 4/11/2024

    FUJIFILM Diosynth Biotechnologies North Carolina, Inc., a world-leading contract development and manufacturing organization (CDMO), will invest $1.2 billion to expand its biopharmaceutical manufacturing facility in Holly Springs, North Carolina, creating 680 new jobs in Wake County.

  10. NorthStar Medical Radioisotopes, LLC Enters Clinical Supply Agreement To Support Clarity Cu-67 SAR-bisPSMA Pivotal Trials 4/10/2024

    NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the signing of a Clinical Supply Agreement with Clarity Pharmaceuticals for the production of 67Cu-SAR-bisPSMA drug product for Clarity’s Phase I/II and Phase III trials.